The US Food and Drug Administration (FDA) has warned GlaxoSmithKline that its Cork manufacturing plant has breached manufacturing regulations.
In a warning letter posted online yesterday, the FDA told GlaxoSmithKline that it found significant violations of current good manufacturing practice (cGMP) regulations at the active pharmaceutical ingredient (API) manufacturing facility in Carrigaline in Co Cork.
The violations were found during an FDA inspection last October, the agency letter said. The agency said these deviations cause...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team